# James Larkin

Source: https://onco.cc/people/james-larkin/  
OnCo record `james-larkin` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Melanoma and kidney cancer trialist who co-led CheckMate 067, the trial with 10-year immunotherapy survival data.

## Summary

James Larkin is a consultant medical oncologist at The Royal Marsden and Professor at The Institute of Cancer Research. His specialisms are melanoma, renal cell carcinoma and immunotherapy combinations. He was a lead investigator of CheckMate 067, the trial of nivolumab plus ipilimumab in advanced melanoma, and of CheckMate 9ER in renal cell carcinoma, work that shaped first-line immunotherapy in both diseases. His New England Journal of Medicine paper reported the long-term results of combined nivolumab and ipilimumab in advanced melanoma from CheckMate 067. His publications are listed on PubMed.

## Fields

- Kind: Person
- Last checked: 2026-09-08
- Role: Consultant Medical Oncologist, Royal Marsden; Professor, ICR
- Specialisms: Melanoma; Renal cell carcinoma; Immunotherapy combinations

## Sources

- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Larkin%20J%5BAuthor%5D%20melanoma%20nivolumab%20ipilimumab

## Connected records

- cancers: [Advanced melanoma (unresectable stage III and stage IV)](https://onco.cc/cancers/advanced-melanoma/), [Melanoma](https://onco.cc/cancers/melanoma/), [Renal cell carcinoma](https://onco.cc/cancers/rcc/)
- drugs: [Ipilimumab](https://onco.cc/drugs/ipilimumab/), [Nivolumab](https://onco.cc/drugs/nivolumab/)
- institutions: [The Institute of Cancer Research](https://onco.cc/institutions/icr-london/), [The Royal Marsden](https://onco.cc/institutions/royal-marsden/)
- trials: [CheckMate 067](https://onco.cc/trials/checkmate-067/), [CheckMate 238](https://onco.cc/trials/checkmate-238/), [CheckMate 9ER](https://onco.cc/trials/checkmate-9er/), [coBRIM](https://onco.cc/trials/cobrim/)
- key papers: [CheckMate 067 at ten years: nivolumab plus ipilimumab produces long-term survival in half of patients with advanced melanoma](https://onco.cc/key-papers/paper-checkmate-067-10-year-nejm-2025/)

---
JSON: https://onco.cc/api/v1/entities/james-larkin.json